Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is duloxetine safe and effective for the treatment of overactive bladder?

Nature Clinical Practice Urology volume 5, pages 188–189 (2008)Cite this article

Steers WD et al. (2007) Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100: 337–345

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Milsom I et al. (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760–766

    Article  CAS  Google Scholar 

  2. Thor KB and Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274: 1014–1024

    CAS  PubMed  Google Scholar 

  3. Dmochowski RR et al. (2003) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170: 1259–1263

    Article  CAS  Google Scholar 

  4. Bent AE et al. (2007) Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourol Urodyn [10.1002/nau.20471]

  5. Thor KB et al. (2007) Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61: 1349–1355

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. M Kirby is a Visiting Professor at the Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, UK ,

    Michael Kirby

  2. Division of Urology, Department of Surgery, KB Thor is Research Associate at the Laboratory of Neurourology, Duke University Medical Center, and is Vice President of Research for Urogenix, Durham, NC, USA.,

    Karl B Thor

Authors
  1. Michael Kirby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl B Thor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kirby.

Ethics declarations

Competing interests

Michael Kirby has received funding from Astellas Pharmaceuticals, Bayer, Eli Lilly and Co., GlaxoSmithKline, MSD and Pfizer for research, advice, lecturing and conference attendance.

Karl B Thor is an employee of Astellas Pharmaceuticals, holds stock in Eli Lilly and Co., and is the inventor on the patent claiming use of duloxetine to treat lower urinary tract dysfunctions.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirby, M., Thor, K. Is duloxetine safe and effective for the treatment of overactive bladder?. Nat Rev Urol 5, 188–189 (2008). https://doi.org/10.1038/ncpuro1077

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1077

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing